Publications by authors named "Geny Piro"

Claim this Profile
P
PI3K/mTORC2-RICTOR axis in early squamous non-small-cell lung cancer: genomics, molecular expression, and clinical relevance.
Sara Pilotto, Lorenzo Belluomini, Federico Monaca, Michele Simbolo, Antonio Agostini, Geny Piro

Ther Adv Med Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COVALENCE STUDY: Immunogenicity and Reactogenicity of a COVID-19 mRNA Vaccine in an Open-Label Cohort of Long-Survivor Patients with Metastatic Lung Cancer.
Emanuele Vita, Federico Monaca, Luca Mastrantoni, Geny Piro, Giacomo Moretti

Vaccines (Basel)· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Local ablation disrupts immune evasion in pancreatic cancer.
Chiara Musiu, Annalisa Adamo, Simone Caligola, Antonio Agostini, Cristina Frusteri, Geny Piro

Cancer Lett· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody-based delivery of interleukin-2 modulates the immunosuppressive tumor microenvironment and achieves cure in pancreatic ductal adenocarcinoma syngeneic mice.
Carmine Carbone, Roberto De Luca, Emanuele Puca, Antonio Agostini, Alessia Caggiano, Geny Piro

J Exp Clin Cancer Res· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The GLP-1R agonist semaglutide reshapes pancreatic cancer associated fibroblasts reducing collagen proline hydroxylation and favoring T lymphocyte infiltration.
Chiara Cencioni, Silvia Malatesta, Virginia Vigiano Benedetti, Valerio Licursi, Livia Perfetto, Geny Piro

J Exp Clin Cancer Res· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential activity of MAPK signalling defines fibroblast subtypes in pancreatic cancer.
Lisa Veghini, Davide Pasini, Rui Fang, Pietro Delfino, Dea Filippini, Geny Piro

Nat Commun· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emerging multisystem biomarkers in hereditary transthyretin amyloidosis: a pilot study.
Marco Luigetti, Francesca Vitali, Angela Romano, Maria Ausilia Sciarrone, Valeria Guglielmino, Geny Piro

Sci Rep· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Axon guidance cue SEMA3A promotes the aggressive phenotype of basal-like PDAC.
Francesca Lupo, Francesco Pezzini, Davide Pasini, Elena Fiorini, Annalisa Adamo, Geny Piro

Gut· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic role of circulating cytokines and inflammation indexes for avelumab maintenance in metastatic urothelial carcinoma.
Brigida Anna Maiorano, Giovanni Schinzari, Carmine Carbone, Geny Piro, Ernesto Rossi

Front Immunol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of spatially-resolved markers of malignant transformation in Intraductal Papillary Mucinous Neoplasms.
Antonio Agostini, Geny Piro, Frediano Inzani, Giuseppe Quero, Annachiara Esposito

Nat Commun· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Role of the Complement in Clear Cell Renal Carcinoma (ccRCC)-What Future Prospects Are There for Its Use in Clinical Practice?
Martina Panebianco, Chiara Ciccarese, Alessandro Strusi, Viria Beccia, Carmine Carbone, Geny Piro

Cancers (Basel)· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Leptin-mediated meta-inflammation may provide survival benefit in patients receiving maintenance immunotherapy for extensive-stage small cell lung cancer (ES-SCLC).
Emanuele Vita, Alessio Stefani, Geny Piro, Luca Mastrantoni, Marco Cintoni

Cancer Immunol Immunother· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment in pancreatic cancer.
Antonio Agostini, Ilaria Guerriero, Geny Piro, Giuseppe Quero, Luca Roberto

J Transl Med· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inflammatory profile in mitochondrial diseases: A cohort study.
Guido Primiano, Domenico Plantone, Geny Piro, Carmine Carbone, Andrea Sabino

Eur J Neurol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune checkpoint blockade therapy mitigates systemic inflammation and affects cellular FLIP-expressing monocytic myeloid-derived suppressor cells in non-progressor non-small cell lung cancer patients.
Annalisa Adamo, Cristina Frusteri, Sara Pilotto, Simone Caligola, Lorenzo Belluomini, Geny Piro

Oncoimmunology· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy.
Enrico Gurreri, Giannicola Genovese, Luigi Perelli, Antonio Agostini, Geny Piro

Int J Mol Sci· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CSF CXCL13 and Chitinase 3-like-1 Levels Predict Disease Course in Relapsing Multiple Sclerosis.
Matteo Lucchini, Valeria De Arcangelis, Geny Piro, Viviana Nociti, Assunta Bianco

Mol Neurobiol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CXCR1/2 dual-inhibitor ladarixin reduces tumour burden and promotes immunotherapy response in pancreatic cancer.
Geny Piro, Carmine Carbone, Antonio Agostini, Annachiara Esposito, Maria De Pizzol

Br J Cancer· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum Inflammatory Profile in Hereditary Transthyretin Amyloidosis: Mechanisms and Possible Therapeutic Implications.
Marco Luigetti, Angela Romano, Valeria Guglielmino, Maria Ausilia Sciarrone, Francesca Vitali, Geny Piro

Brain Sci· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unweaving the mitotic spindle: A focus on Aurora kinase inhibitors in lung cancer.
Alessio Stefani, Geny Piro, Francesco Schietroma, Alessandro Strusi, Emanuele Vita

Front Oncol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Generation and validation of an IL-12 fusion protein based on a novel anti-human FAP monoclonal antibody.
Lisa Nadal, Frederik Peissert, Abdullah Elsayed, Tobias Weiss, Thomas Look, Geny Piro

J Immunother Cancer· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenic Cell Death: An Emerging Target in Gastrointestinal Cancers.
Marta Chiaravalli, Alexia Spring, Antonio Agostini, Geny Piro, Carmine Carbone

Cells· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting hypoxia-inducible factor pathways in sporadic and Von Hippel-Lindau syndrome-related kidney cancers.
Roberto Iacovelli, Daniela Arduini, Chiara Ciccarese, Francesco Pierconti, Alessandro Strusi, Geny Piro

Crit Rev Oncol Hematol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gastrointestinal Cancer Patient Nutritional Management: From Specific Needs to Novel Epigenetic Dietary Approaches.
Chiara Cencioni, Ilaria Trestini, Geny Piro, Emilio Bria, Giampaolo Tortora

Nutrients· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pancreatic Cancer Patient-Derived Organoid Platforms: A Clinical Tool to Study Cell- and Non-Cell-Autonomous Mechanisms of Treatment Response.
Geny Piro, Antonio Agostini, Alberto Larghi, Giuseppe Quero, Carmine Carbone

Front Med (Lausanne)· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis